Zacks Equity Research 04/07/2020 12:59 AM ET Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now? Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. Coherus BioSciences Inc. company facts, information and stock details by MarketWatch. View chrs business summary and other industry information. CHRS Coherus BioSciences, Inc. Common Stock. Data is currently not available. $19.16. 0.49 (2.62%) DATA AS OF Jun 02, 2020. Latest News. Our vendor, Zacks Investment Research, hasn't provided The Zacks Consensus Estimate for CHRS's full-year earnings has moved 53.01% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is
Coherus BioSciences News | Markets Insider Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year? Zacks 152d Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference Coherus (CHRS) to Report Q4 Earnings: What's in the ...
Zacks Investment Research cut shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the […] Has Coherus BioSciences (CHRS) Outpaced Other Medical ... Jan 23, 2020 The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA ... Nov 12, 2019 CHRS - Coherus Biosciences Summary, Stock Quote and News ... Jan 01, 2010
May 03, 2020 Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now? Mar 26, 2020
Coherus BioSciences, Inc. (CHRS) Stock Analysis & News ... Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now? at Zacks.com (Mar 26, 2020) Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals Coherus Biosciences (NASDAQ:CHRS) Upgraded by Zacks ... Zacks Investment Research upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a hold rating to a buy rating in a report issued on Monday morning, Zacks.com reports. The firm currently has $25.00 price target on the biotechnology company’s stock. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here ... Coherus BioSciences (CHRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?